Objective: To analyze radiographic signs of temperomandibular joint (TMJ) osteoarthritis and clinical TMJ symptoms in patients 6 years and 32 years after treatment with a Herbst appliance.

Materials And Methods: Fourteen patients were derived from a sample of 22 with Class II division 1 malocclusions consecutively treated with a banded Herbst appliance at the age of 12-14 years old (T1-T2). The subjects were reexamined after therapy at the ages of 20 years (T3) and 46 years (T4). The TMJs of the 14 patients were analyzed radiographically (conventional lateral tomography at T3 and cone-beam computed tomography at T4) and clinically/anamnestically at T3 and T4.

Results: Six years after Herbst therapy, signs of osteoarthritis were seen in one patient. At the 32-year follow-up, two additional patients had developed signs of osteoarthritis. At the 6-year follow-up, TMJ clicking was present in two patients, though none of the patients reported TMJ pain. At the 32-year follow-up, six patients had TMJ clicking and one patient had TMJ pain.

Conclusions: This longitudinal very-long-term follow-up study after Herbst therapy revealed only minor problems from the TMJ. The TMJ findings 6 years and 32 years after Herbst treatment corresponded to those in the general population. Thus, in the very long term, the Herbst appliance does not appear to be harmful to the TMJ.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610386PMC
http://dx.doi.org/10.2319/072914-530.1DOI Listing

Publication Analysis

Top Keywords

herbst therapy
12
years years
12
tmj
10
follow-up study
8
years
8
herbst appliance
8
years herbst
8
signs osteoarthritis
8
32-year follow-up
8
tmj clicking
8

Similar Publications

The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP).

View Article and Find Full Text PDF

Intervention accelerator to prevent and respond to abuse of older people: insights from key promising interventions.

Lancet Healthy Longev

December 2024

Department of Social Determinants of Health, Division of Healthier Populations, WHO, Geneva, Switzerland.

Globally, abuse of older people (AOP) affects one in six individuals aged 60 years and older every year. Despite the widespread prevalence of AOP, evidence-based interventions for preventing and responding to this issue are insufficient. To address this gap, WHO proposed an initiative to accelerate the development of effective interventions for AOP across all country income levels.

View Article and Find Full Text PDF
Article Synopsis
  • Patients on long-term opioid therapy for chronic pain often still suffer from unrelieved pain and quality of life issues.
  • This study compared two approaches for managing these patients: an integrated pain team (IPT) focused on holistic care versus pharmacist collaborative management (PCM) concentrated on medication optimization.
  • Results showed similar outcomes for both groups in terms of pain response and opioid dosage reduction after 12 months, indicating that both methods can be effective in managing chronic pain.
View Article and Find Full Text PDF

Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through the modulation of coagulation and platelet activity. Both have been found to play an important role in the tumor microenvironment, tumor growth and metastasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!